![Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference](https://www.degruyter.com/document/doi/10.1515/cclm-2021-0399/asset/graphic/j_cclm-2021-0399_fig_001.jpg)
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
![Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland | Future Oncology Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2023-0120/asset/images/medium/figure2.gif)
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland | Future Oncology
![Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study | JACC: CardioOncology Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study | JACC: CardioOncology](https://www.jacc.org/cms/asset/2d32c323-2cc4-4e94-bbdf-071752ae731c/fx1.jpg)
Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study | JACC: CardioOncology
![JCDD | Free Full-Text | Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights JCDD | Free Full-Text | Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights](https://www.mdpi.com/jcdd/jcdd-10-00484/article_deploy/html/images/jcdd-10-00484-g001-550.jpg)
JCDD | Free Full-Text | Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights
![Frontiers | Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study Frontiers | Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study](https://www.frontiersin.org/files/Articles/632535/fneur-12-632535-HTML/image_m/fneur-12-632535-g001.jpg)
Frontiers | Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study
![IgG2a, Kappa from murine myeloma clone UPC 10, purified immunoglobulin, buffered aqueous solution | Sigma-Aldrich IgG2a, Kappa from murine myeloma clone UPC 10, purified immunoglobulin, buffered aqueous solution | Sigma-Aldrich](https://www.sigmaaldrich.com/deepweb/assets/sigmaaldrich/product/images/337/550/5f9273a6-8dc7-41ba-8bc9-066f618b3315/640/5f9273a6-8dc7-41ba-8bc9-066f618b3315.jpg)
IgG2a, Kappa from murine myeloma clone UPC 10, purified immunoglobulin, buffered aqueous solution | Sigma-Aldrich
![Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy - William I Deighan, Maurice J O'Kane, Feargal P McNicholl, Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy - William I Deighan, Maurice J O'Kane, Feargal P McNicholl,](https://journals.sagepub.com/cms/10.1177/0004563216646594/asset/images/large/10.1177_0004563216646594-fig1.jpeg)